New data confirms effectiveness of NovoMix 30 in diabetes

The meta-analysis evaluated the results of nine clinical trials comparing NovoMix 30 with biphasic human insulin in a total of 1,674 type II and 151 type I diabetes patients. NovoMix 30 was shown to be associated with a 35% relative risk reduction (p=0.005) of nocturnal hypoglycaemia and a 59% relative risk reduction (p<0.01) of major hypoglycaemic events compared to biphasic human insulin across trials. These results provide strong evidence of a clinically important reduced risk of nocturnal and major hypoglycaemia with NovoMix 30. Dr Jaime Davidson of the Endocrine & Diabetes Association of Texas, US, said: “These results are significant because many people with diabetes live in fear of a hypoglycaemic event. It is particularly a concern at night when glucose levels can drop more frequently and go undetected by the sleeping individual. Any treatment which can be relied upon to cause as few episodes of hypoglycaemia as possible during these periods is welcome.” The results support those of a key study published in Diabetes Care earlier in 2007, which showed that NovoMix 30 is associated with less nocturnal hypoglycaemia than biphasic human insulin in insulin-treated type 2 diabetes patients. Dr Robert Ligthelm, consultant physician and doctor of internal medicine, commented: “NovoMix 30 is a part of the ongoing evolution of diabetes treatments as their understanding of the condition grows. With its lower risk of nocturnal and major hypoglycaemic events compared to biphasic human insulin, it represents in essence an upgrade from traditional human insulin.”